The good news on the vaccine: Novavax vaccine with 90% efficacy expected to be launched in September, trials may start on children from July

The US-based company Novavax’s vaccine may be launched in India in September. It will be made in India by the Serum Institute of India (SII) under the name of Kovax. SII said on Thursday that we are preparing to launch the vaccine in India in September. There is a plan to start its clinical trial on children from July.

Trials in
Britain The results of the third phase of Novavax’s trial in Britain have come. Earlier on Monday, the company had told that it has proved to be very effective against the corona virus. The vaccine has shown 90.4% final efficiencies in mild, moderate and severe cases.

Due to the better results, soon this vaccine is expected to get approval for emergency use. This vaccine has also been effective in protecting against different variants. The company has released these results amid the worldwide vaccine shortage.

The Serum Institute of India (SII) is currently producing the CoviShield vaccine.

Novavax to prepare 200 crore doses and Indian company SII have signed an agreement to prepare 200 crore doses of Corona vaccine. The deal was signed in August. According to the agreement, at least 100 million doses will be produced for low and middle income countries and India.

Now after the results of the trial, the company can seek approval for emergency use in the US, UK and Europe in the third quarter of 2021.

Novavax has started trials on children of its vaccine abroad. The company has started trials on 3,000 children in the age group of 12-17 years. However, it has not yet been approved in any country. Children participating in this will be monitored for 2 years.

America has already done 12 thousand crore deal
Novavax has signed an agreement to give 100 million doses to America. This deal is worth 1.6 billion dollars (about Rs 12 thousand crores). Along with this, agreements have also been made with Britain, Canada, and Japan for the supply of vaccines.

Related Posts